Showing 1451-1460 of 5758 results for "".
DermwireTV: Pharma Partnership Boosts Spesolimab, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pharma-partnership-boosts-spesolimab-plus-more/36519/In this episode of Dermwire TV, two pharma leaders partner to commercialize SPEVIGO for patients with generalized pustular psoriasis; interest in red light devices is up; and experts take a look at what’s new in psoriasis treatments on the Practical Dermatology Podcast.FDA Grants Interchangeability to HADLIMA
https://practicaldermatology.com/series/dermwire-tv/fda-grants-interchangeability-to-hadlima/35962/In this week's DermwireTV, the FDA grants full interchangeability to HADLIMA; new research shows the impact of UV exposure on global skin cancer cases; and coverage from Music City SCALE addresses barriers to patient access to new therapies.Rosacea Comorbidities and Skincare with Energy-Based Devices
https://practicaldermatology.com/programs/practical-dermatology/rosacea-comorbidities-and-skincare-with-energy-based-devices/35895/Ted Lain, MD, MBA, discusses the gut-skin connection as it relates to rosacea, as well as skincare with energy-based devices, at Music City SCALE 2025.Seborrheic Dermatitis Approaches and Stopping Biologic Treatment for Atopic Dermatitis
https://practicaldermatology.com/conferences/scale-2025/seborrheic-dermatitis-approaches-and-stopping-biologic-treatment-for-atopic-dermatitis/35896/Naiem T. Issa, MD, PhD, talks at Music City SCALE 2025 about how to approach seborrheic dermatitis, as well as what happens to atopic dermatitis patients after ending biologic treatments.Nail Disease and JAK Inhibitor Safety
https://practicaldermatology.com/programs/practical-dermatology/nail-disease-and-jak-inhibitor-safety/35897/Brad Glick, DO, talks about the basics of nail anatomy, physiology, disease presentation, and treatments, as well as the safety of JAK inhibitors, at Music City SCALE 2025.Study Examines Socioeconomic Status and HS Diagnosis
https://practicaldermatology.com/series/dermwire-tv/study-examines-socioeconomic-status-and-hs-diagnosis/35859/In this week's DermwireTV, a new study examines the association between socioeconomic status and HS diagnosis; a new meta-analysis highlights the therapeutic potential of simvastatin for vitiligo; and in our “Updates on Skin Cancer” feature, we hear about how to use gene expression profile testing fDermWire TV Extra: Spironolactone on TikTok
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-extra-spironolactone-on-tiktok/33016/George Washington University clinical instructor of Dermatology Emily Murphy, MD, and medical student Savanna Vidal discuss their research regarding the quality and reliability of information on TikTok about spironolactone for acne treatment.AAD Leaders Discuss New Goals and Initiatives
https://practicaldermatology.com/series/dermwire-tv/aad-leaders-discuss-new-goals-and-initiatives/33154/In this week's DermwireTV, leaders of the American Academy of Dermatology (AAD) discuss the key issues facing the specialty; a new study examines nicotinamide exposure and the risk of major adverse cardiovascular events; and in our C-Suite Chats segment, we hear from an Executive Director at TakeDr. Anderson on New Tech That ‘Could be Revolutionary’ at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-anderson-on-new-tech-that-could-be-revolutionary-at-maui-derm/32921/In-vivo microscopy that will change how dermatologists practice and potentially revolutionary drug delivery systems were among the technologies highlighted by R. Rox Anderson, MD, PhD, during “Innovation in Dermatology 2025: A Look Into the Future of Dermatology” at the Maui Derm Hawaii 2025 meetingMaui Derm Panel: GLP-1 Agonists Can Help Psoriasis Patients
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/maui-derm-panel-glp-1-agonists-can-help-psoriasis-patients/32917/Only 11% of Maui Derm 2025 audience members polled said they were comfortable prescribing weight-loss drugs, and 49% said they were not at all—but they should be, according to the presenters of “Psoriasis Update 2025” at the conference in Maui, Hawaii.